- In June 2025, Novo Nordisk announced its plan to initiate Phase III clinical trials for Amycretin, a dual GLP-1 and amylin receptor agonist aimed at treating obesity and type 2 diabetes. Following highly promising mid-stage results, where patients experienced a 22% weight loss in 36 weeks with the injectable version, the company is advancing both oral and injectable formulations. This development reflects Novo Nordisk’s continued leadership in the incretin therapeutics space and its commitment to expanding patient-friendly treatment options
- In April 2025, Eli Lilly announced successful results from its Phase III ACHIEVE-1 trial for Orforglipron, an oral GLP-1 receptor agonist designed for type 2 diabetes and obesity treatment. The trial reported up to 1.6-point reductions in HbA1c and 8% average weight loss over 40 weeks. This milestone positions Orforglipron as a strong oral alternative to injectable GLP-1 therapies and showcases Eli Lilly’s focus on innovative, needle-free treatment modalities to enhance patient adherence
